ICULIP, Influence of Two Lipid Emulsions in the Nosocomial Infection in Critical Patients

NCT ID: NCT00396461

Last Updated: 2013-07-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 212 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2011-02-28

Brief Summary

This study aims to analyse the effect of two total parenteral nutrition diets with lipid emulsions of different compositions on the incidence of nosocomial infection in critical patients. One diet will contain an MCT/LCT emulsion concentrated to 20% (50:50 ratio) and the other will comprise an MCT/LCT/fish oil emulsion (50:40:10 ratio). The secondary objective of this study is to analyse mortality in hospital and up to 6 months of discharge.

Detailed Description

During the last years the most widely used lipid emulsion for parenteral nutrition has been based on soybean oil. This first generation of lipid emulsions used in TPN contained w-6 series polyunsaturated long-chain fatty acids (LCT) from soy, maize, sunflower and safflower oil. LCT contain an excess of linoleic acid which, when metabolised, produce large quantities of arachidonic acid and its metabolites. Although the generally used doses seem safe (1-2 g/kg/day by continuous perfusion), alterations in pulmonary function in patients with acute adult respiratory distress syndrome have been described, as have alterations in platelet function, hepatic function and haemodynamics, which are attributed to the excess of said metabolites. However, the most important side effect of the LCT lipid infusions is its influence on the immune response. Experimental and clinical studies show that LCT can interfere with various stages of the immune response such as the production of antibodies, complement synthesis, granulocytic and lymphocytic activity and the reticuloendothelial system. Various hypotheses have been formulated to explain the modulator effect of the polyunsaturated fatty acids on immune function: changes in the permeability of the cellular membrane, modifications in the synthesis of eicosanoids and the presence of peroxides derived from the oxidation of polyunsaturated fatty acids.

In summary, although linoleic acid as a dietary essential fatty acid is important, its excessive intake is associated with undesirable immunological and inflammatory events. Thus it is recommended that soybean oil should be partly replaced by other lipids.

To avoid these side effects the second generation lipid emulsions were developed. These contain a combination of medium- and long-chain fatty acids (MCT/LCT) with lower w-6 fatty acid content. MCT/LCT lipid emulsions are safe and do not produce biochemical or metabolic alterations or gaseous exchange in patients with ARDS. MCT/LCT combinations seem to reduce the generation of eicosanoids and do not alter the immune response in in-vitro and experimental studies. The impact of these differences on the nosocomial infection and the clinical prognosis of the patients has not been studied sufficiently despite the fact that some studies show reduced mortality and morbidity using MCT/LCT emulsions when compared with the use of pure LCT emulsions. MCT/LCT emulsions are normally used in clinical practice on patients that have required parenteral nutrition for 20 years.

Recently, the clinical use in artificial nutrition of omega-3 series polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) present in many fish oils has been significant. EPA is a precursor to certain eicosanoid series that compensate the proinflammatory effects of the eicosanoids in arachidonic acid (omega-6 series). The objective is immunomodulation to attenuate the inflammatory response of patients without negatively impacting on the immune function. The use of enteral diets enriched with omega-3 series fatty acids (fish oil) in post-operation cancer patients showed a reduction in the number of days in hospital and infectious complications.

The use of fish oil or fat emulsions enriched with fish oil (omega-3) in parenteral nutrition has already been the subject of various studies: where modulation of the inflammatory response markers has been shown, reduces the stay in hospital and the need for mechanical ventilation in patients undergoing major abdominal surgery, reduces the stay in hospital in patients undergoing digestive surgery… So, w-3 lipids exhibit strong immunologic properties. They offer the possibility to counterbalance the negative effects of conventional w-6 fatty acids. Recent studies exhibit positive effects of intravenous use of fish oil on immunologic functions and clinical parameters in surgical and septic patients

The purpose of this study is to analyse the effect of two total parenteral nutrition diets with lipid emulsions of different compositions on the incidence of nosocomial infection in critical patients. One diet will contain an MCT/LCT emulsion concentrated to 20% (50:50 ratio) (w3:w6 is 1:7) and the other will comprise an MCT/LCT/fish oil emulsion (50:40:10 ratio) (w3:w6 is 1:2,7). The secondary objective of this study is to analyse mortality in hospital and up to 6 months after discharge.

Conditions

Critical Illness

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

TPN A (Group I)

Emulsion based on 20% MCT/LCT (50:50 ratio)

Group Type: ACTIVE_COMPARATOR

MCT/LCT (1:1)

Intervention Type: DRUG

Emulsion based on 20% MCT/LCT (50:50 ratio)

TPN B (Group II)

Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides

Group Type: EXPERIMENTAL

MCT/LCT/omega-3 (5:4:1)

Intervention Type: DRUG

Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.

Interventions

MCT/LCT (1:1)

Emulsion based on 20% MCT/LCT (50:50 ratio)

Intervention Type: DRUG

MCT/LCT/omega-3 (5:4:1)

Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.

Intervention Type: DRUG

Other Intervention Names

LIPOFUNDINA; LIPOPLUS

Eligibility Criteria

Inclusion Criteria

Patients of both sexes, prospective admission to Intensive Care Units (ICUs), over 18 years, where TPN is required as a nutritional metabolic support for a minimum period of 5 days and where said patients have signed the informed consent form.

The indications for administration of parenteral nutrition shall be those recommended by the American Society of Parenteral and Enteral Nutrition (ASPEN), and in particular:

• Severe malnutrition
• Major intra-abdominal surgery
• Peritonitis
• Intestinal ischaemia
• Intestinal occlusion
• Gastrointestinal fistulas
• Small intestine

Patients of both sexes, over 18 years, that commencing nutritional support with enteral diets in the first 3 days of admission to ICU require parenteral nutrition as:

• 75% of the calculated energy requirements have not been reached after three days receiving enteral nutrition.
• Gastrointestinal complications have been suffered as a result of enteral nutrition that cannot be treated or are persistent in the first 3 days of admission.

In this case EN will be suspended and the patient will be included in the protocol receiving PN.

Exclusion Criteria

• APACHE II < 13
• Morbid obesity (BMI ≥ 39)
• Hepatic disease defined within the following set of parameters:

1. Portal hypertension with gastrointestinal bleeding on admission

2. Clinically apparent hepatocellular ascites

3. Hepatocellular bilirubin higher than 3 mg/dL

4. Serum albumin less than 30 g/L with portal hypertension

5. Grade II or higher encephalopathy

6. Clinical diagnosis of alcoholic hepatitis

• Chronic renal insufficiency defined by one of the following criteria:

1. Plasmatic creatinine greater than 4 mg/dL

2. Chronic peritoneal dialysis or haemodialysis

• Patients with severe acquired or familial hyperlipidaemias (> 400 mg/day) of any kind
• Serious chronic neurological disease defined by one of the following criteria:

1. Cerebrovascular accident with persistent neurological deficit in the past six months

2. Neurological deficit that necessitates chronic confinement

• Neoplastic patients with metastasis and a life expectancy of less than six months
• Patients that underwent chemotherapy or radiotherapy during the month prior to the study
• Patients that received chronic treatment with corticoids in the month preceding admission to ICU. Patients receiving treatment with corticoids since admission to ICU for septic shock should not be excluded.
• Continuous infusion treatment for more than 24 hours with propofol or with other pharmaceuticals where lipid emulsions are used as the vehicle
• Infectious diseases transmitted through the blood, products derived from blood or urine: hepatitis B, C and HIV
• Inclusion in another clinical trial
• Having received TPN in the month prior to inclusion in the study
• Pregnancy
• Refusal to participate in the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

B. Braun Medical SA

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Abelardo García de Lorenzo, MD

Role: STUDY_CHAIR

Hospital Universitario La Paz

Alfonso Bonet Saris, MD_Study Coordinator

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Girona Dr. Josep Trueta

Teodoro Grau Carmona, MD_Study Coordinator

Role: STUDY_CHAIR

Hospital Severo Ochoa Leganés (Madrid)

Locations

Hospital General Universitario de Alicante

Alicante, Alicante, Spain

Hospital Son Dureta

Palma de Mallorca, Balearic Islands, Spain

Hospital del Mar (Institut Municipal d'Assistència Sanitària, IMAS)

Barcelona, Barcelona, Spain

Hospital Universitari Vall d'Hebrón

Barcelona, Barcelona, Spain

Hospital Universitario de Bellvitge (H.U.B.)

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital de Cruces

Barakaldo, Bizcaya, Spain

Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain

Hospital Universitario "Puerta del Mar"

Cadiz, Cádiz, Spain

Hospital Universitari de Girona Doctor Josep Trueta

Girona, Girona, Spain

Hospital Universitario de Gran Canaria Dr. Negrín

Las Palmas de Gran Canaria, Gran Canaria, Spain

Complejo Hospitalario Materno Insular de Gran Canaria

Las Palmas de Gran Canaria, Gran Canaria, Spain

Hospital Universitario Virgen de las Nieves

Granada, Granada, Spain

Hospital Universitario Arnau de Vilanova

Lleida, Lleida, Spain

Hospital Severo Ochoa

Leganés, Madrid, Spain

Fundación Jiménez Díaz

Madrid, Madrid, Spain

Hospital Universitario "Virgen de la Arrixaca"

El Palmar, Murcia, Spain

Hospital General Universitario "Reina Sofía"

Murcia, Murcia, Spain

Hospital Regional Universitario Carlos Haya

Málaga, Málaga, Spain

Hospital Universitario de Valme

Seville, Sevilla, Spain

Hospital Clínico Universitario de Valencia

Valencia, Valencia, Spain

Hospital Universitario Del Río Hortega

Valladolid, Valladolid, Spain

Hospital Universitario Miguel Servet

Zaragoza, Zaragoza, Spain

Countries

Spain

References

Cerra FB. Hypermetabolism, organ failure, and metabolic support. Surgery. 1987 Jan;101(1):1-14.

Reference Type: BACKGROUND

PMID: 3541266 (View on PubMed)

Garcia-de-Lorenzo A. Lipid emulsions with different phospholipid/triglyceride ratio in critically ill septic and traumatic patients. Crit Care Med. 1998 Dec;26(12):2094-5. doi: 10.1097/00003246-199812000-00049. No abstract available.

Reference Type: BACKGROUND

PMID: 9875927 (View on PubMed)

Bach AC, Frey A, Lutz O. Clinical and experimental effects of medium-chain-triglyceride-based fat emulsions--a review. Clin Nutr. 1989 Oct;8(5):223-35. doi: 10.1016/0261-5614(89)90032-0.

Reference Type: BACKGROUND

PMID: 16837294 (View on PubMed)

Mathru M, Dries DJ, Zecca A, Fareed J, Rooney MW, Rao TL. Effect of fast vs slow intralipid infusion on gas exchange, pulmonary hemodynamics, and prostaglandin metabolism. Chest. 1991 Feb;99(2):426-9. doi: 10.1378/chest.99.2.426.

Reference Type: BACKGROUND

PMID: 1989806 (View on PubMed)

Gogos CA, Kalfarentzos F. Total parenteral nutrition and immune system activity: a review. Nutrition. 1995 Jul-Aug;11(4):339-44.

Reference Type: BACKGROUND

PMID: 8580573 (View on PubMed)

Calder PC, Sherrington EJ, Askanazi J, Newsholme EA. Inhibition of lymphocyte proliferation in vitro by two lipid emulsions with different fatty acid compositions. Clin Nutr. 1994 Apr;13(2):69-74. doi: 10.1016/0261-5614(94)90062-0.

Reference Type: BACKGROUND

PMID: 16843362 (View on PubMed)

Clarke PJ, Ball MJ, Hands LJ, Dennison AR, Tunbridge A, White K, Kettlewell MG. Use of a lipid containing medium chain triglycerides in patients receiving TPN: a randomized prospective trial. Br J Surg. 1987 Aug;74(8):701-4. doi: 10.1002/bjs.1800740818.

Reference Type: BACKGROUND

PMID: 3115354 (View on PubMed)

Barton RG. Nutrition support in critical illness. Nutr Clin Pract. 1994 Aug;9(4):127-39. doi: 10.1177/0115426594009004127.

Reference Type: BACKGROUND

PMID: 8078451 (View on PubMed)

Suchner U, Katz DP, Furst P, Beck K, Felbinger TW, Senftleben U, Thiel M, Goetz AE, Peter K. Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. Crit Care Med. 2001 Aug;29(8):1569-74. doi: 10.1097/00003246-200108000-00012.

Reference Type: BACKGROUND

PMID: 11505129 (View on PubMed)

Gogos CA, Kalfarentzos FE, Zoumbos NC. Effect of different types of total parenteral nutrition on T-lymphocyte subpopulations and NK cells. Am J Clin Nutr. 1990 Jan;51(1):119-22. doi: 10.1093/ajcn/51.1.119.

Reference Type: BACKGROUND

PMID: 2136970 (View on PubMed)

Jensen GL, Mascioli EA, Seidner DL, Istfan NW, Domnitch AM, Selleck K, Babayan VK, Blackburn GL, Bistrian BR. Parenteral infusion of long- and medium-chain triglycerides and reticuloendothelial system function in man. JPEN J Parenter Enteral Nutr. 1990 Sep-Oct;14(5):467-71. doi: 10.1177/0148607190014005467.

Reference Type: BACKGROUND

PMID: 2122019 (View on PubMed)

Suchner U, Senftleben U. Immune modulation by polyunsaturated fatty acids during nutritional therapy: interactions with synthesis and effects of eicosanoids. Infusionsther Transfusionsmed. 1994 Jun;21(3):167-82. doi: 10.1159/000222968.

Reference Type: BACKGROUND

PMID: 7919904 (View on PubMed)

Calder PC. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. Braz J Med Biol Res. 2003 Apr;36(4):433-46. doi: 10.1590/s0100-879x2003000400004. Epub 2003 Apr 8.

Reference Type: BACKGROUND

PMID: 12700820 (View on PubMed)

Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE, Van Hoozen C, Wennberg AK, Nelson JL, Noursalehi M. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med. 1999 Aug;27(8):1409-20. doi: 10.1097/00003246-199908000-00001.

Reference Type: BACKGROUND

PMID: 10470743 (View on PubMed)

Weiss G, Meyer F, Matthies B, Pross M, Koenig W, Lippert H. Immunomodulation by perioperative administration of n-3 fatty acids. Br J Nutr. 2002 Jan;87 Suppl 1:S89-94. doi: 10.1079/bjn2001461.

Reference Type: BACKGROUND

PMID: 11895158 (View on PubMed)

Koller M, Senkal M, Kemen M, Konig W, Zumtobel V, Muhr G. Impact of omega-3 fatty acid enriched TPN on leukotriene synthesis by leukocytes after major surgery. Clin Nutr. 2003 Feb;22(1):59-64. doi: 10.1054/clnu.2002.0592.

Reference Type: BACKGROUND

PMID: 12553951 (View on PubMed)

Tsekos E, Reuter C, Stehle P, Boeden G. Perioperative administration of parenteral fish oil supplements in a routine clinical setting improves patient outcome after major abdominal surgery. Clin Nutr. 2004 Jun;23(3):325-30. doi: 10.1016/j.clnu.2003.07.008.

Reference Type: BACKGROUND

PMID: 15158295 (View on PubMed)

ASPEN Board of Directors: Guidelines for the use of parenteral and enteral nutrition in adults and pediatric patients. JPEN 2001

Reference Type: BACKGROUND

Carpentier YA, Van Gossum A, Dubois D, Deckeibaum R. Lipid Metabolism in Parenteral Nutrition. In: Wilmore DW, Carpentier YA (Eds). Metabolic Support of the Critically III Patient. Berlin, Springer-Veriag 1993, pp 35-74

Reference Type: BACKGROUND

Driscoll DF, Adolph M, Bistrian BR. Lipid emulsions in parenteral nutrition. In: Rombeau JL, Rolandelli R, eds. Parenteral nutrition. Philadelphia: W. B. Saunders Company; 2000:35-39.

Reference Type: BACKGROUND

Santoli D, Zurier RB. Prostaglandin E precursor fatty acids inhibit human IL-2 production by a prostaglandin E-independent mechanism. J Immunol. 1989 Aug 15;143(4):1303-9.

Reference Type: BACKGROUND

PMID: 2545787 (View on PubMed)

Kinsella JE, Lokesh B. Dietary lipids, eicosanoids, and the immune system. Crit Care Med. 1990 Feb;18(2 Suppl):S94-113. No abstract available.

Reference Type: BACKGROUND

PMID: 2105185 (View on PubMed)

Kumar SG, Das UN, Kumar KV, Madhavi N, Das NP, Tan BKH. Effect of n-6 and n-3 fatty acids on the proliferation of human lymphocyes and their secretion of TN F-alpha and IL-2 in vitro. Nutr Res 1992; 12: 815-823.

Reference Type: BACKGROUND

Grau T, Ruiz de Adana JC, Zubillaga S, Fuerte S, Giron C. [Randomized study of two different fat emulsions in total parenteral nutrition of malnourished surgical patients;effect of infectious morbidity and mortality]. Nutr Hosp. 2003 May-Jun;18(3):159-66. Spanish.

Reference Type: BACKGROUND

PMID: 12875092 (View on PubMed)

Grimminger F, Seeger W, Mayer K. Use of n-3 fatty acid-containing lipid emulsions in the intensive care unit environment: the clinician's view. Clinical Nutrition 2002, 21, Supplement 2: 23-29.

Reference Type: BACKGROUND

Wichmann MW, Morlion B, Czarnetzki H-D, Thul P, Jauch K-W. Reduction of length of postoperative stay by fish oil containing lipid emulsion - data from a multicenter trial. Clinical Nutrition 2004, 23: 1471

Reference Type: BACKGROUND

Related Links

http://www.senpe.com

Spanish Society for Parenteral and Enteral Nutrition

http://www.nutritioncare.org/

ASPEN, American Society for Parenteral and Enteral Nutrition --\> Nutrition-related Links

http://www.semicyuc.org/

Spanish Society for Intensive Medicine, Critical and Coronary Units

Other Identifiers

2005-003542-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

HC-G-H-0510

Identifier Type: -

Identifier Source: org_study_id